In a report released today, Matthew Weston from UBS maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback